This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
462
Peking University People's Hospital
Beijing, Beijing Municipality, China
Percent Change from Baseline in Body Weight
Time frame: Week 60
Proportion of Participants who Achieve ≥5% Body Weight Reduction
Time frame: Week 60
Proportion of Participants who Achieve ≥10% Body Weight Reduction
Time frame: Week 60
Proportion of Participants who Achieve ≥15% Body Weight Reduction
Time frame: Week 60
Proportion of Participants who Achieve ≥20% Body Weight Reduction
Time frame: Week 60
Change from Baseline in Waist Circumference
Time frame: Week 60
Change from Baseline in Systolic Blood Pressure
Time frame: Week 60
Percent Change from Baseline in Triglycerides
Time frame: Week 60
Percent Change from Baseline in non-high-density lipoprotein cholesteroal
Time frame: Week 60
Percent Change from Baseline in low-density lipoprotein cholesterol
Time frame: Week 60
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.